2024

1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

   The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

2. Cardiovascular surgery and cardiology, current status of two sister specialties in Spain: the CARDIOXCARDIO study

   Revista Espanola de Cardiologia

3. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

   British Journal of Surgery, Vol. 111, Núm. 3

4. Clinical suspicion, diagnosis and management of cardiac amyloidosis: update and executive summary

   Revista Clinica Espanola, Vol. 224, Núm. 5, pp. 288-299

5. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

   European Journal of Nuclear Medicine and Molecular Imaging

6. Combinational Diuretics in Heart Failure

   Current Heart Failure Reports

7. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

   Breast Cancer Research and Treatment

8. Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure

   ESC Heart Failure

9. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

   Clinical Genitourinary Cancer, Vol. 22, Núm. 1, pp. 56-66

10. Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

11. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

12. Is trimodal therapy the current standard for muscle-invasive bladder cancer?

    Actas Urologicas Espanolas

13. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure

14. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713

15. Pellagra linked to maize consumption in Gambo, Ethiopia: A call for awareness

    Journal of the European Academy of Dermatology and Venereology

16. Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

    Frontiers in Cardiovascular Medicine, Vol. 11

17. Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document

    Endocrine

18. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

19. Prognosis of acute heart failure in patients followed up in nursing homes in Spain: Results from the RICA registry

    Medicina Clinica, Vol. 162, Núm. 4, pp. 157-162

20. Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism

    Endocrine